<DOC>
	<DOCNO>NCT02240888</DOCNO>
	<brief_summary>The overall objective project study influence modern anti-inflammatory treatment establish inflammatory rheumatic disease ( IRD ) immune response elicit pneumococcal vaccination use 13-valent conjugate vaccine influenza vaccination . In addition , aim study clinical aspect vaccination regarding : tolerability immunosuppressed patient IRD , impact exist rheumatic disease , possible association onset new autoimmune disease , long-term immunity follow pneumococcal vaccination , efficacy prevent invasive pneumococcal disease influenza relate serious infection . Results study expected bridge exist knowledge gap contribute body evidence need recommendation implementation vaccination program IRD patient .</brief_summary>
	<brief_title>Vaccination Inflammatory Rheumatic Disease ( VACCIMIL ) . The Impact Antirheumatic Treatment Antibody Response Protection Infections</brief_title>
	<detailed_description />
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Adult patient IRD receive active antirheumatic treatment DMARDs biological remedy offer participate study . The protocol permit stratification prednisolone usage , smoke habit alcohol consumption . age &lt; 18 year ; pregnancy , know intolerance vaccine , ongoing infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>pneumococcal</keyword>
	<keyword>vaccination</keyword>
	<keyword>antibody</keyword>
	<keyword>response</keyword>
	<keyword>immunosuppressive</keyword>
	<keyword>treatment</keyword>
	<keyword>inflammatory</keyword>
	<keyword>rheumatic</keyword>
	<keyword>disease</keyword>
</DOC>